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Abstract
We endeavored to identify objective blood biomarkers for pain, a subjective sensation with a biological basis, using a
stepwise discovery, prioritization, validation, and testing in independent cohorts design. We studied psychiatric patients, a
high risk group for co-morbid pain disorders and increased perception of pain. For discovery, we used a powerful within-
subject longitudinal design. We were successful in identifying blood gene expression biomarkers that were predictive of pain
state, and of future emergency department (ED) visits for pain, more so when personalized by gender and diagnosis.
MFAP3, which had no prior evidence in the literature for involvement in pain, had the most robust empirical evidence from
our discovery and validation steps, and was a strong predictor for pain in the independent cohorts, particularly in females and
males with PTSD. Other biomarkers with best overall convergent functional evidence for involvement in pain were GNG7,
CNTN1, LY9, CCDC144B, and GBP1. Some of the individual biomarkers identiﬁed are targets of existing drugs.
Moreover, the biomarker gene expression signatures were used for bioinformatic drug repurposing analyses, yielding leads
for possible new drug candidates such as SC-560 (an NSAID), and amoxapine (an antidepressant), as well as natural
compounds such as pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), and apigenin (a plant ﬂavonoid). Our work
may help mitigate the diagnostic and treatment dilemmas that have contributed to the current opioid epidemic.
Introduction
“ The greatest evil is physical pain”
– Saint Augustine
Pain is a subjective feeling with objective roots and
profound evolutionary biological utility. It reﬂects per-
ceived or actual damage to the organism [1, 2]. Mental
states can affect the perception of pain, and in turn be
affected by pain. Psychiatric patients may have an
increased perception of pain, as well as increased physi-
cal health reasons for pain, due to their often adverse life
trajectory [3]. As such, they may be a particularly suitable
population in which to try to identify peripheral blood
biomarkers for pain, that may be complementary to
genetic ﬁndings in the ﬁeld [4]. Of note, a number of
psychiatric medications are currently used to treat pain
disorders [5]. Given these close inter-relationships, we
expect our ﬁndings to be generalizable, trans-diagnostic,
and have general relevance to pain, independent of spe-
ciﬁc psychiatric disorders.
First, we used a powerful longitudinal within-subject
design in individuals with psychiatric disorders to discover
blood gene expression changes between self-reported
low pain and high pain states. Second, we prioritized the
list of candidate biomarkers with a Bayesian-like Con-
vergent Functional Genomics approach, comprehensively
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integrating previous published human and animal model
evidence in the ﬁeld for involvement in pain, and
directly citing it. Third, we validated our top biomarkers
from discovery and prioritization in an independent cohort
of psychiatric subjects with a clinical diagnosis of a
pain disorder and with high scores on pain severity
and functional impact ratings. Fourth, we tested if the
candidate biomarkers from the ﬁrst three steps are able to
predict high pain state, and future emergency department
(ED) visits for pain, in another independent cohort of
psychiatric subjects. We tested the biomarkers in all sub-
jects in the independent test cohort, as well as in a more
personalized fashion by gender and psychiatric diagnosis,
showing increased accuracy with the personalized
approach. Fifth, we assessed if our biomarkers have evi-
dence for involvement in other psychiatric and related dis-
orders, as well as analyzed the biological pathways and
networks they are involved in. Sixth, we bioinformatically
identiﬁed which of our individual biomarkers are modulated
by existing drugs and thus can be used for pharmacoge-
nomic population stratiﬁcation and measuring of response
to treatment, as well as used the gene expression signatures
of the top predictive biomarkers to interrogate the
Connectivity Map database from Broad/MIT to identify
drugs and natural compounds that could be repurposed for
treating pain.
Materials and methods
Cohorts
We used three independent cohorts: discovery (major psy-
chiatric disorders), validation (major psychiatric disorders
with clinically severe pain disorders), and testing (an
independent major psychiatric disorders cohort for predict-
ing pain state, and for predicting future ED visits for pain)
(Fig. 1a).
Similar to our previous studies [6–8], the psychiatric
subjects are part of a larger longitudinal cohort of adults
that we are continuously collecting. Subjects were
recruited from the patient population at the Indianapolis
VA Medical Center. All subjects understood and signed
informed consent forms detailing the research goals,
procedure, caveats and safeguards, per Indiana University
IRB approved protocol. Subjects completed diagnostic
assessments by an extensive structured clinical interview
—Diagnostic Interview for Genetic Studies, and up to six
testing visits, 3–6 months apart or whenever a new psy-
chiatric hospitalization occurred. At each testing visit,
they received a series of rating scales, including a visual
analog scale (1–10) for assessing pain and the SF 36
quality of life scale, which has two pain-related items
(items 21 and 22), and the blood was drawn. We collected
whole blood (10 ml) in two RNA-stabilizing PAXgene
tubes, labeled with an anonymized ID number, and stored
at −80 ºC in a locked freezer until the time of future
processing. Whole-blood RNA was extracted for micro-
array gene expression studies from the PAXgene tubes, as
detailed below.
For this study, our within-subject discovery cohort, from
which the biomarker data were derived, consisted of
28 subjects (19 males, 9 females) with multiple testing
visits, who each had at least one diametric change in pain
from Low Pain (VAS of 2 and below) to High Pain (VAS of
6 and above) from one testing visit to another (Fig. 1b and
Fig. S1). There were three subjects with ﬁve visits each, one
subject with four visits, twelve subjects with three visits
each, and twelve subjects with two visits each resulting in a
total of 79 blood samples for subsequent gene expression
microarray studies (Fig. 1 and Table S1).
Our validation cohort, in which the top biomarker ﬁnd-
ings were validated for being even more changed in
expression, consisted of 13 male and 10 female subjects
with a pain disorder diagnosis and clinically severe pain
(Table S1). This was determined as having a pain VAS of 6
and above and a sum of SF36 scale items 21 (pain intensity)
and 22 (impairment by pain of daily activities) of 10 and
above (Table S1).
Our independent test cohort for predicting state (High
Pain) consisted of 134 male and 28 female subjects with
psychiatric disorders, demographically matched with the
discovery cohort, with one or multiple testing visits in our
lab, with either Low Pain, intermediate Pain, or High Pain,
resulting in a total of 414 blood samples in which whole-
genome blood gene expression data were obtained (Fig. 1
and Table S1).
Our test cohort for predicting trait (future ED visits with
pain as the primary reason in the ﬁrst year of follow-up, and
all future ED visits for pain) (Fig. 1) consisted of 171 males
and 19 female subjects for which we had longitudinal
follow-up with electronic medical records. The subjects’
subsequent number of ED pain-related visits in the year
following testing was tabulated from electronic medical
records by a clinical researcher, who used the key word
“pain” in the reasons for ED visit, or “ache” with a mention
of acute pain in the text of the note.
Medications
The subjects in the discovery cohort were all diagnosed
with various psychiatric disorders, and had various medical
co-morbidities (Table 1). Their medications were listed in
their electronic medical records, and documented by us at
the time of each testing visit. Medications can have a strong
inﬂuence on gene expression. However, our discovery of
502 A. B. Niculescu et al.
differentially expressed genes was based on within-subject
analyses, which factor out not only genetic background
effects but also minimizes medication effects, as the sub-
jects rarely had major medication changes between visits.
Moreover, there was no consistent pattern of any particular
type of medication, as our subjects were on a wide variety
of different medications, psychiatric and non-psychiatric.
Some subjects may be non-compliant with their treatment
Fig. 1 Steps 1–3: Discovery, prioritization, and validation. a Cohorts
used in study, depicting ﬂow of discovery, prioritization, and valida-
tion of biomarkers from each step. b Discovery cohort longitudinal
within-subject analysis. Phchp### is study ID for each subject. V#
denotes visit number. c Discovery of possible subtypes of Pain based
on High Pain visits in the discovery cohort. Subjects were clustered
using measures of mood and anxiety (Simpliﬁed Affective State Scale
(SASS)), as well as psychosis (PANNS Positive). d Differential gene
expression in the Discovery cohort—number of genes identiﬁed with
differential expression (DE) and absent-present (AP) methods with an
internal score of 2 and above. Red—increased in expression in High
Pain, blue—decreased in expression in High Pain. At the discovery
step probesets are identiﬁed based on their score for tracking pain with
a maximum of internal points of 6 (33% (2 pt), 50% (4 pt), and 80%
(6 pt)). e Prioritization with CFG for prior evidence of involvement in
pain. In the prioritization step, probesets are converted to their asso-
ciated genes using Affymetrix annotation and GeneCards. Genes are
prioritized and scored using CFG for pain evidence with a maximum
of 12 external points. Genes scoring at least six points out of a max-
imum possible of 18 total internal and external scores points are car-
ried to the validation step. f Validation in an independent cohort of
psychiatric patients with co-morbid pain disorders and severe sub-
jective and functional pain ratings. In the validation step biomarkers
are assessed for stepwise change from the discovery groups of subjects
with Low Pain, to High Pain, to Clinically Severe Pain disorder, using
ANOVA. N= number of testing visits. Five biomarkers were nom-
inally signiﬁcant, MFAP3 and PIK3CD were the most signiﬁcant, and
68 biomarkers were stepwise changed
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and may thus have changes in medications or drug of abuse
not reﬂected in their medical records. That being said, our
goal is to ﬁnd biomarkers that track pain, regardless if the
reason for it is endogenous biology or driven by substance
abuse or medication non-compliance. In fact, one would
expect some of these biomarkers to be targets of medica-
tions, as we show in this paper. Overall, the discovery of
biomarkers with our universal design occurs despite the
subjects having different genders, diagnoses, being on
various different medications, and other lifestyle variables.
Blood gene expression experiments
RNA extraction
Whole blood (2.5–5 ml) was collected into each PaxGene
tube by routine venipuncture. PaxGene tubes contain
proprietary reagents for the stabilization of RNA. RNA was
extracted and processed as previously described [6–8].
Microarrays
Microarray work was carried out using previously described
methodology [6–9]. and as described below.
Biomarkers
Step 1: Discovery
We have used the subject’s score from the VAS Pain Scale,
assessed at the time of blood collection (Fig. 1). We ana-
lyzed gene expression differences between visits with Low
Pain (deﬁned as a score of 0–2) and visits with High Pain
(deﬁned as a score of 6 and above), using a powerful
Table 1 Aggregate Demographics
Cohorts Number of
subjects
Gender Diagnosis Ethnicity Age at
time of
visit
Mean
(SD)
T-test for age
Discovery
Discovery cohort (longitudinal
withinsubject changes in pain
scale (1–10)) Low Pain 0–2 to
High Pain 6–10
28 (with 79
visits)
Male = 19
Female = 9
BP = 9
MDD= 3
SZA= 6
SZ= 3
PTSD= 5
PSYCH= 2
EA= 17
AA= 10
Mixed = 1
52 (7.94)
Validation
Independent validation cohort
(clinical Severe pain diagnosis
SF36 sum of scores on
questions 21 and 22 ≥ 10 Pain
scale ≥ 6)
23 (30
visits)
Male = 13
Female = 10
MDD=8
BP=6
SZ=2
SZA=2
PTSD=2
MOOD=3
EA= 17
AA= 6
51.9 (7.1)
Testing
Independent testing cohort for
predicting State (High Pain
State Pain Scale ≥6 at time of
assessment)
162 (411
visits)
Male = 134
Female = 28
BP=52
MDD=39
SZA=19
SZ=26
PTSD=20
MOOD=4
PSYCH=2
EA= 112
AA= 48
Hispanic=2
50.3
(8.97)
Others
50.12
High Pain
50.50
High Pain (n=101)
Vs. Others
(n=310)
0.824
Independent testing cohort for
predicting trait (Future ED
visits for pain in the ﬁrst year
following assessment)
181 (470
visits)
Male = 163
Female = 18
BP = 46
MDD= 33
SZA= 45
SZ= 38
PTSD= 13
MOOD= 4
PSYCH= 2
EA= 117
AA= 62
Hispanic = 2
52.45
(6.13)
Others
52.61 ED
visits for
Pain
51.87
ED visits for Pain
(n=102) vs. Others
(n=368)
0.237
Independent testing cohort for
predicting trait (Future ED
visits for pain in All Years
following assessment)
189 (501
visits)
Male = 170
Female = 19
BP = 49
MDD= 34
SZA= 45
SZ= 40
PTSD=15
MOOD= 4
PSYCH= 2
EA= 124
AA= 62
Hispanic=3
51.79
(6.75)
Others
51.58 ED
visits for
Pain
52.02
ED visits for Pain
(n=239) vs. Others
(n=262)
0.4720
MDD depression, BP bipolar, SZ schizophrenia, SZA schizoaffective, PSYCHOSIS schizophrenia and schizoaffective combined, PTSD post-
traumatic stress disorder
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within-subject design, then an across-subjects summation
(Fig. 1).
We analyzed the data in two ways: an Absent-Present
(AP) approach, and a differential expression (DE) approach,
as in previous work by us on suicide biomarkers [6–8].
The AP approach may capture turning on and off of genes,
and the DE approach may capture gradual changes
in expression. Analyses were performed as previously
described [7–9]. We have developed in our labs R scripts to
automate and conduct all these large dataset analyses in
bulk, checked against human manual scoring [9].
Gene Symbol for the probesets were identiﬁed using
NetAffyx (Affymetrix) for Affymetrix HG-U133 Plus 2.0
GeneChips, followed by GeneCards to conﬁrm the primary
gene symbol. In addition, for those probesets that were not
assigned a gene symbol by NetAffyx, we used GeneAnnot
(https://genecards.weizmann.ac.il/geneannot/index.shtml)
to obtain gene symbols for these uncharacterized probesets,
followed by GeneCard. Genes were then scored using our
manually curated CFG databases as described below
(Fig. 1e).
Step 2: Prioritization using Convergent Functional
Genomics (CFG)
Databases: We have established in our laboratory
(Laboratory of Neurophenomics, www.neurophenomics.
info) manually curated databases of the human gene
expression/protein expression studies (postmortem brain,
peripheral tissue/ﬂuids: CSF, blood and cell cultures),
human genetic studies (association, copy number variations
and linkage), and animal model gene expression and genetic
studies, published to date on psychiatric disorders. Only
ﬁndings deemed signiﬁcant in the primary publication, by
the study authors, using their particular experimental design
and thresholds, are included in our databases. Our databases
include only primary literature data and do not include
review papers or other secondary data integration analyses
to avoid redundancy and circularity. These large and con-
stantly updated databases have been used in our CFG cross
validation and prioritization platform (Fig. 1e). For this
study, data from 355 papers on pain were present in the
databases at the time of the CFG analyses (December 2017)
(human genetic studies-212, human nervous tissue studies-
3, human peripheral tissue/ﬂuids- 57, non-human genetic
studies-26, non-human brain/nervous tissue studies-48,
non-human peripheral tissue/ﬂuids- 9). Analyses were per-
formed as previously described [7, 8].
Step 3: Validation analyses
Validation analyses of our candidate biomarker genes were
conducted separately for AP and for DE. We examined
which of the top candidate genes (total CFG score of 6 or
above), were stepwise changed in expression from the Low
Pain and High Pain group to the Clinically Severe Pain
group. A CFG score of 6 or above reﬂects an empirical
cutoff of 33.3% of the maximum possible CFG score of 12,
which permits the inclusion of potentially novel genes with
maximal internal score of 6 but no external evidence score.
Subjects with Low Pain, as well as subjects with High
Pain from the discovery cohort who did not have severe
clinical pain (SF36 sum of item 21 and 22 < 10) were used,
along with the independent validation cohort which all had
severe clinical pain and a co-morbid pain disorder diagnosis
(n= 23).
For the AP analyses, we imported the Affymetrix
microarray.chp data ﬁles from the subjects in the validation
cohort of Clinically Severe Pain into MAS5 Affymetrix
Expression Console, alongside the data ﬁles from the Low
Pain and High Pain groups in the live discovery cohort. We
transferred the AP data to an Excel sheet and transformed A
into 0, M into 0.5, and P into 1. We then Z-scored every-
thing together by gender and diagnosis. If a probeset would
have showed no variance and thus gave a non-determined
(0/0) value in Z-scoring in a gender and diagnosis, we
would have excluded the values from that probeset for that
gender and diagnosis from the analysis.
For the DE analyses, the cohorts (Validation Clinically
Severe Pain, alongside the Low Pain and High Pain groups
in the Discovery cohort) were assembled out of Affymetrix
.cel data that was RMA normalized by gender and diag-
nosis. We transferred the log transformed expression data to
an Excel sheet, and non-log transformed the data by taking
2 to the power of the transformed expression value. We then
Z-scored the values by gender and diagnosis.
We then imported the Excel sheets with the Z-scored by
gender and diagnosis AP and DE expression data into
Partek, and statistical analyses were performed using a one-
way ANOVA for the stepwise changed probesets, and also
attempted a stringent Bonferroni corrections for all the
probesets tested (Figure 1F). We also wrote an R script that
automatically analyzes the data directly from the Excel
sheet, and used that to conﬁrm our calculations.
Choice of biomarkers to be carried forward
We carried forward into testing the top biomarkers from
each step. The longer list of candidate biomarkers
includes the top biomarkers from discovery step ( ≥ 90%
of scores, n= 28), the top biomarkers from the prior-
itization step (CFG score ≥ 8, n= 32), and the nominally
signiﬁcant biomarkers after the validation step (n= 5), for
a total of n= 65 probesets (n= 60 genes). The short list of
top biomarkers after the validation step is ﬁve biomarkers.
In Step 4, testing, we then predict with the biomarkers
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from the long list in independent cohorts High Pain state,
and future ED visits for pain in the ﬁrst year, and in all
future years.
Diagnostics
The test cohort for predicting High Pain (state), and
the subset of it that is a test cohort for predicting future
ED visits (trait), were assembled out of data that was
RMA normalized by gender and diagnosis. The cohort
was completely independent, there was no subject overlap
with the discovery cohort. Phenomic (clinical) and
gene expression markers used for predictions were Z-scored
by gender and diagnosis, to be able to combine different
markers into panels and to avoid potential artefacts due to
different ranges of expression in different gender and
diagnoses. Markers were combined by simple summation of
the increased risk markers minus the decreased risk mar-
kers. Predictions were performed using R-studio.
Predicting state-high pain state
Receiver-operating characteristic (ROC) analyses between
genomic and phenomic marker levels and Pain were
performed by assigning subjects with a Pain score of 6
and greater into the High Pain category. We used the pROC
package of R (Xavier Robin et al. BMC Bioinformatics
2011). We used the Z-scored biomarker and phene
scores, running them in this ROC generating program
against the diagnostic groups in the independent test
cohort (High Pain vs. the rest of subjects). Additionally, a
one-tailed t-test was performed between High Pain group
vs. the rest, and Pearson R (one-tail) was calculated between
Pain scores and marker levels (Supplementary Information-
Complete Datasets and Analyses).
Predicting trait-future ED visits for pain in ﬁrst year
following testing
We conducted analyses for predicting ED visits for pain
in the ﬁrst year following each testing visit, in subjects
that had at least 1 year of follow-up in the VA system, for
which we have access to complete electronic medical
records. ROC analyses between genomic and phenomic
marker levels at a speciﬁc testing visit and future ED
visits for pain were performed as described above, based
on assigning if subjects had visited the ED with primary
reason for pain or not within 1 year following a testing
visit. Additionally, a one tailed t-test with unequal var-
iance was performed between groups of subject visits
with and without ED visits for Pain. Pearson R (one-tail)
correlation was performed between hospitalization fre-
quency (number of ED visits for Pain divided by duration
of follow-up) and marker levels. A Cox regression was
performed using the time in days from the testing visit
date to ﬁrst ED visit date in the case of patients who had
been to the ED, or 365 days for those who did not. The
hazard ratio was calculated such that a value >1 always
indicates increased risk for ED visits, regardless if the
biomarker is increased or decreased in expression.
We also conducted odds ratio analyses for ED visits
for pain for all future ED visits due to pain, including
those occurring beyond 1 year of follow-up, in the years
following testing (on average 5.56 years per subject,
range 0.44 to 11.27 years; see Table 1 and Table S1), as
this calculation, unlike the ROC and t-test, accounts for
the actual length of follow-up, which varied from subject
to subject. The ROC and t-test might in fact, if
used, under-represent the power of the markers to predict,
as the more severe psychiatric patients are more likely to
move geographically and/or be lost to follow-up. A Cox
regression was also performed using the time in
days from visit date to ﬁrst ED Pain visit date in the case
of patients who had been to the ED for Pain, or from
visit date to last note date in the electronic medical
records for those who did not. The hazard ratio was cal-
culated such that a value >1 always indicates increased
risk for ED Pain-related visits, regardless if the biomarker
is increased or decreased in expression.
Biological understanding
Pathway analyses
IPA (Ingenuity Pathway Analyses, version 24390178,
Qiagen), David Functional Annotation Bioinformatics
Microarray Analysis (National Institute of Allergy and
Infectious Diseases) version 6.7 (August 2016), and Kyoto
Encyclopedia of Genes and Genomes (KEGG) (through
DAVID) were used to analyze the biological roles, includ-
ing top canonical pathways and diseases (Table S4), of the
candidate genes resulting from our work, as well as to
identify genes in our dataset that are the target of existing
drugs. We ran the pathway analyses for the combined AP
and DE probesets 60 unique genes (65 probesets). For
Network analysis of the 60 unique genes we performed
STRING Interaction Network (https://string-db.org) by in
putting the genes into the search window and performed
Multiple Proteins Homo sapiens analysis.
CFG beyond Pain: evidence for involvement in other
psychiatric and related disorders
We also used a CFG approach to examine evidence from
other psychiatric and related disorders, for the long list of 65
candidate biomarkers (Table S3).
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Therapeutics
Pharmacogenomics
We analyzed which of our individual top biomarkers is
known to be modulated by existing drugs using our CFG
databases, and using Ingenuity Drugs analyses (Table S4).
New drug discovery/repurposing
We also analyzed which drugs and natural compounds are
an opposite match for the gene expression proﬁle of panels
of our top biomarkers (n= 65), using the Connectivity Map
(https://portals.broadinstitute.org, Broad Institute, MIT)
(Table 3). Thirty-three out of 65 probesets were present in
the HGU-133A array used for the Connectivity Map.
Convergent functional evidence (CFE)
We tabulated into a convergent functional evidence
(CFE) score all the evidence from discovery (up to 6
points), prioritization (up to 12 points), validation (up to
6 points), testing (state, trait ﬁrst year ED visits, trait all
future ED visits- up to 8 points each if signiﬁcantly
predicts in all subjects, 6 points if predicts by gender, 4
points if predicts in gender/diagnosis). The total score can
be up to 48 points: 36 from our data and 12 from literature
data. We weigh our data three times as much as the lit-
erature data. The goal is to highlight, based on the totality
of our data and of the evidence in the ﬁeld to date, bio-
markers that have all around evidence: track pain,
are reﬂective of pain pathology, and predict it. Such
biomarkers merit priority evaluation in future clinical
trials.
Results
First, we used a discovery cohort composed of subjects with
psychiatric disorders followed longitudinally over time [6–
11], in which each subject had blood samples collected and
neuropsychological testing done in at least one low pain
state visit (Pain VAS ≤ 2 out of 10) and at least one high
pain state visit (Pain VAS ≥ 6 out of 10) (Fig. 1 and
Fig. S1).
We used a powerful longitudinal within-subject design
[6–12] in individuals to discover blood gene expression
changes between self-reported low pain and high pain
states. A longitudinal within-subject design is orders of
magnitude more powerful than a cross-sectional case-con-
trol design. Some of these candidate gene expression bio-
markers are increased in expression in high pain states
(being putative risk genes, or “algogenes”), and others are
decreased in expression (being putative protective genes, or
“pain suppressor genes”).
Second, we prioritized this list of candidate biomarkers
with a Bayesian-like Convergent Functional Genomics
approach [13, 14], comprehensively integrating previous
published human and animal model evidence in the ﬁeld for
involvement in pain, and directly citing it.
Third, we further validated our top biomarkers from
discovery and prioritization in an independent cohort of
psychiatric subjects also carrying a clinical diagnosis of a
pain disorder, and with high scores on pain severity and
functional impairment ratings.
We ended up with a list of 65 candidate biomarkers
(Table 2 and S2, S3, S5) from the ﬁrst three steps, including
a shorter list of ﬁve validated biomarkers (MFAP3,
PIK3CD, SVEP1, TNFRSF11B, ELAC2). The biomarkers
with the best evidence after validation were Hs.666804/
MFAP3 (p= 6.03E-04) and PIK3CD (p= 1.59E-02).
Fourth, we tested if the 65 candidate biomarkers are able to
predict pain severity state, and future emergency department
(ED) visits for pain, in another independent cohort of psy-
chiatric subjects. We used biomarker levels information cross-
sectionally, as well as expanded longitudinal information
about biomarker levels at multiple visits, as predictors. We
tested the biomarkers in all subjects in the test cohort, as well
as in a more personalized fashion by gender and psychiatric
diagnosis, showing increased accuracy with the personalized
approach, in particular in women (Fig. 2). Across all subjects
tested, CNTN1 was the best predictor for state (AUC 63%,
p= 0.0014), GBP1 the best predictor for trait ﬁrst year ED
visits (AUC 59%, p= 0.0035), and GNG7 the best predictor
for trait all future ED visits (OR 1.28, p= 0.00013, surviving
Bonferroni correction for the 65 biomarkers tested). By gen-
der, in females, DNAJC18 was the best predictor for state
(AUC 78%, p= 0.0049), GBP1 the best predictor for trait
ﬁrst year ED visits (AUC 71%, p= 0.043) and ASTN2 for
trait all future ED visits (OR 2.45, p= 0.044). In males,
CNTN1 was the best predictor for state (AUC 63%, p=
0.0022), Hs.554262 the best predictor for trait ﬁrst year ED
visits (AUC 59%, p= 0.016), and MFAP3 the best predictor
for trait all future ED visits (OR 1.35, p= 0.0089). Persona-
lized by gender and diagnosis, in female bipolar CDK6 was a
strong predictor for state (AUC 100%, p= 0.007), in female
PTSD SHMT1 was a strong predictor for trait ﬁrst year ED
visits (AUC 100%, p= 0.022), and in female depression
GNG7 for trait all future ED visits (OR 14.54, p= 0.022). In
male depression CASP6 was a strong predictor for state
(AUC 87%, p= 0.00007, surviving Bonferroni correction for
the 65 biomarkers tested), in male PTSD LY9 was a strong
predictor for trait ﬁrst year ED visits (AUC 77%, p= 0.041),
and in male PTSD MFAP3 was a strong predictor for trait all
future ED visits (OR 15.93, p= 0.00085). In general, panels
of all 65 top biomarkers or of the ﬁve validated biomarkers
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Table 2 Convergent functional evidence (CFE) for top candidate biomarkers for pain (n= 60 genes, 65 probesets)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
GNG7
G Protein subunit
gamma 7
1566643_a_at (D)
DE/4 59%
6 6.81E-02/2
Stepwise
All
C:(101/411)
0.56/3.52E-02
Gender
Male
C:(85/346)
0.56/3.95E-02
Gender/Dx
M-SZ
C:(11/64)
0.68/2.79E-02
Gender
Females
C:(7/44)
0.7/4.92E-02
Gender/Dx
F-MDD
C:(4/11)
0.82/4.45E-02
L:(2/6)
1/3.20E-02
F-PTSD
C:(2/8)
0.92/4.78E-02
All
C:(239/501)
1.28/1.03E-04a
L:(145/309)
1.22/1.70E-02
Gender
Females
C:(13/47)
1.69/4.69E-02
Males
C:(226/454) 1.28/1.92E-04a
L:(138/282) 1.21/2.16E-02
Gender/Dx
F-MDD
C:(4/12)
14.54/2.23E-02
M-MDD
L:(25/43)
1.8/2.70E-02
M-PSYCHOSIS
C:(95/201)
1.52/1.70E-04a
L:(57/120)
1.34/2.47E-02
M-SZ
C:(42/103)
1.58/2.08E-02
M-SZA
C:(53/98)
1.71/4.40E-04a
Alcohol
BP
Hallucinogens
MDD
Stress
SZ
Omega-3 fatty
acids
34
CNTN1
Contactin 1
1554784_at (D)
DE/4 52%
6 NS All
C:(101/411)
0.58/1.15E-02
L:(61/248)
0.63/1.42E-03
Gender
Female
C:(16/65)
0.65/3.38E-02
Male
L:(51/212)
0.63/2.27E-03
Gender/Dx
M-BP
C:(24/123)
0.61/4.13E-02
L:(16/81)
0.64/4.06E-02
M-SZ
C:(11/64)
0.68/3.15E-02
M-MDD
L:(13/43)
0.66/4.53E-02
M-SZA
L:(3/17) 0.83/
3.89E-02
Gender
Males
C:(95/426)
0.56/3.08E-02
Gender/Dx
M-MDD
C:(42/72)
1.44/1.23E-02
L:(25/43)
1.64/4.17E-02
BP
MDD
SZ
Suicide
Clozapine 28
LY9
Lymphocyte
antigen 9
231124_x_at (I)
DE/6 90%
2 NS All
C:(101/411)
0.56/4.40E-02
L:(61/248)
0.58/2.39E-02
Gender
Male
C:(85/346)
0.57/3.02E-02
L:(51/212)
0.62/5.19E-03
Gender/Dx
M-BP
C:(24/123)
0.63/2.66E-02
F-MDD
C:(2/18)
0.97/1.75E-02
M-MDD
L:(13/43)
0.8/9.87E-04
All
C:(102/470)
0.56/2.30E-02
Gender
Males
C:(95/426)
0.59/2.61E-03
Gender/Dx
M-BP
C:(18/120)
0.68/6.91E-03
M-PTSD
L:(10/16)
0.77/4.13E-02
Gender/Dx
M-MDD
C:(42/72)
1.65/3.85E-03
L:(25/43)
1.53/3.74E-02
M-PTSD
L:(18/20)
2.07/6.77E-03
Acute stress Omega-3 fatty
acids
28
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
CCDC144B
Coiled-coil domain
containing 144B
(pseudogene)
1557366_at (D)
DE/4 56%
6 NS Gender/Dx
F-BP
C:(4/21)
0.79/3.66E-02
M-PSYCHOSIS
C:(19/96)
0.68/8.95E-03
L:(10/56)
0.68/4.16E-02
M-SZA
L:(3/17)
0.9/1.61E-02
Gender/Dx
M-MDD
C:(26/67)
0.63/3.43E-02
All
C:(239/501)
1.23/2.27E-03
Gender
Males
C:(226/454)
1.23/3.34E-03
Gender/Dx
M-PSYCHOSIS
C:(95/201)
1.41/3.46E-03
L:(57/120)
1.43/1.32E-02
M-SZ
C:(42/103)
1.84/4.65E-03
M-SZA
L:(32/56)
1.47/3.49E-02
26
GBP1
Guanylate binding
protein 1
231578_at (I)
DE/2 37%
6 3.26E-01/2
Stepwise
All
C:(102/470)
0.59/3.51E-03
Gender
Females
C:(7/44)
0.71/4.30E-02
Males
C:(95/426)
0.58/1.04E-02
Gender/Dx
F-MDD
C:(4/11)
0.93/1.17E-02
M-PSYCHOSIS
C:(33/198)
0.6/3.25E-02
M-SZA
C:(23/97)
0.62/4.10E-02
All
C:(239/501)
1.09/3.72E-02
Gender
Females
C:(13/47)
1.68/2.41E-02
Gender/Dx
F-MDD
C:(4/12)
3.1/4.43E-02
M-SZA
C:(53/98)
1.22/3.65E-02
MDD
PTSD
SZ
Omega-3 fatty
acids
26
Hs.666804/ MFAP3
Microﬁbril
associated protein 3
240949_x_at (D)
DE/6 81%
0 6.03E-04/4
Nominal
Gender/Dx
F-PTSD
C:(5/12)
0.8/4.41E-02
Gender/Dx
M-BP
L:(9/80)
0.75/7.27E-03
All
L:(145/309)
1.28/2.28E-02
Gender
Males
C:(226/454)
1.17/2.64E-02
L:(138/282)
1.35/8.94E-03
Gender/Dx
M-BP
L:(34/91)
2.36/4.86E-04a
M-PTSD
L:(18/20)
15.93/8.46E-04
Alcohol
Suicide
Stress
26
CASP6
Caspase 6
209790_s_at (I)
DE/4 51%
4 NS Gender
Male
L:(51/212)
0.59/2.92E-02
Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
M-MDD
L:(13/43)
0.87/7.01E-05a
Gender
Males
C:(95/426)
0.57/2.54E-02
Gender/Dx
M-PSYCHOSIS
C:(33/198)
0.6/2.88E-02
M-SZA
C:(23/97)
0.63/2.71E-02
Gender/Dx
M-MDD
C:(42/72)
1.31/3.97E-02
BP 24
COMT
Catechol-O-
methyltransferase
216204_at (D)
DE/4 54%
4 NS Gender/Dx
M-MDD
L:(13/43)
0.71/1.41E-02
All
C:(102/470)
0.55/4.48E-02
Gender
Males
C:(95/426)
0.57/1.95E-02
Gender/Dx
M-MDD
C:(26/67)
0.66/1.58E-02
M-PSYCHOSIS
C:(33/198)
0.6/3.63E-02
Gender/Dx
M-BP
L:(34/91)
1.65/2.20E-02
ADHD
Aggression
Alcohol
Anxiety
BP
Chronic stress
MDD
OCD
Panic disorder
Psychosis
PTSD
Suicide SZ
Clozapine
Morphine
Mood stabilizers
24
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
RAB33A
RAB33A, member
RAS oncogene
family
206039_at (I)
DE/6 90%
0 NS Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
Gender
Males
C:(95/426)
0.56/3.60E-02
All
C:(239/501)
1.14/2.21E-02
Gender
Males
C:(226/454)
1.16/1.01E-02
Gender/Dx
M-BP
L:(34/91)
1.65/1.69E-03
M-MDD
C:(42/72)
1.95/6.59E-04a
L:(25/43)
1.85/1.72E-02
Alcohol
Stress
MDD
24
ZYX
Zyxin
238016_s_at (D)
DE/4 57%
4 NS Gender/Dx
F-BP
C:(4/21)
0.78/4.44E-02
All
C:(102/470)
0.55/4.80E-02
Gender
Males
C:(95/426)
0.57/1.58E-02
Gender/Dx
M-PSYCHOSIS
C:(33/198)
0.62/1.43E-02
M-SZA
C:(23/97)
0.66/1.15E-02
M-BP
L:(9/80)
0.71/2.26E-02
Gender/Dx
M-BP
L:(34/91)
1.85/1.67E-02
M-PTSD
C:(26/31)
1.57/4.40E-02
L:(18/20)
2.2/1.53E-02
MDD Clozapine 24
(Hs.696420)
MTERF1
Mitochondrial
transcription
termination factor 1
243125_x_at (D)
DE/6
100%
0 NS Gender/Dx
M-PSYCHOSIS
C:(19/96)
0.67/1.01E-02
M-SZ
C:(11/64)
0.77/2.27E-03
L:(7/39)
0.71/3.95E-02
Gender/Dx
F-PTSD
C:(2/8)
1/2.28E-02
All
C:(239/501)
1.19/1.19E-02
L:(145/309)
1.2/4.81E-02
Gender
Males
C:(226/454)
1.19/1.51E-02
Gender/Dx
M-PSYCHOSIS
C:(95/201)
1.41/8.86E-03
M-SZ
C:(42/103)
1.4/4.47E-02
M-SZA
C:(53/98)
1.44/4.72E-02
PTSD
Suicide
22
COL27A1
Collagen type
XXVII alpha 1
chain
225293_at (D)
DE/4 79%
4 7.47E-01/2
Stepwise
Gender/Dx
M-MDD
L:(13/43)
0.66/4.79E-02
Gender/Dx
M-MDD
C:(26/67)
0.63/3.38E-02
M-PSYCHOSIS
C:(33/198)
0.61/2.79E-02
M-SZA
C:(23/97)
0.68/4.96E-03
L:(13/55) 0.7/
1.62E-02
Gender/Dx
M-PTSD
L:(18/20)
1.96/2.37E-02
Tourette syndrome Lithium 22
HRAS
HRas proto-
oncogene, GTPase
212983_at (I)
DE/6 97%
0 NS All
C:(101/411)
0.56/3.47E-02
L:(61/248)
0.58/3.01E-02
Gender
Male
C:(85/346)
0.57/2.72E-02
L:(51/212)
0.61/1.18E-02
Gender/Dx
M-SZ
C:(11/64)
0.68/2.79E-02
M-MDD
Gender/Dx
F-PTSD
C:(2/8)
1/2.28E-02
Gender/Dx
M-MDD
C:(42/72)
2.2/3.38E-06a
L:(25/43)
2.25/2.61E-04a
Alcohol
BP
Longevity suicide
SZ
ISIS 2503 22
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
L:(13/43)
0.71/1.61E-02
CALCA
Calcitonin related
polypeptide alpha
210727_at (D)
DE/4 54%
7 NS Gender
Females
C:(16/63)
0.66/3.12E-02
Gender/Dx
F-MDD
C:(2/18)
0.97/1.75E-02
F-BP
L:(3/11)
0.88/3.31E-02
M-MDD
L:(13/43)
0.66/4.79E-02
Gender/Dx
F-PTSD
C:(2/8)
1/2.28E-02
Gender/Dx
M-PSYCHOSIS
C:(33/198)
0.6/3.87E-02
Alcohol
Anxiety
Panic disorder
Omega-3 fatty
acids
Lithium
21
(Hs.596713)
PPP1R14B
Protein phosphatase
1 regulatory
inhibitor subunit
14B
226138_s_at (D)
DE/6 90%
0 6.28E-02/2
Stepwise
Gender/Dx
F-BP
C:(4/21)
0.94/3.61E-03
L:(3/11)
0.92/2.06E-02
M-MDD
L:(13/43)
0.73/9.98E-03
All
C:(239/501)
1.15/1.43E-02
Gender
Males
C:(226/454)
1.19/4.84E-03
L:(138/282)
1.2/3.94E-02
Gender/Dx
M-PSYCHOSIS
C:(95/201)
1.35/3.06E-03
M-SZ
C:(42/103)
1.53/3.19E-02
M-SZA
C:(53/98)
1.41/9.26E-03
SZ Lithium 20
ASTN2
Astrotactin 2
1554816_at (I)
DE/6 83%
2 1.71E-01
/2
Stepwise
Gender/Dx
F-MDD
L:(2/6)
1/3.20E-02
Gender
Female
L:(7/27)
2.45/4.36E-02
Suicide
SZ
ASD
BP
MDD
Antipsychotics 20
ELAC2
ElaC ribonuclease
Z 2
201766_at (D)
DE/4 52%
2 4.11E-02/4
Nominal
Gender/Dx
M-MDD
L:(13/43)
0.73/8.66E-03
Gender
Males
L:(138/282)
1.2/4.61E-02
Gender/Dx
M-BP
L:(34/91)
1.55/4.79E-02
M-MDD
C:(42/72)
1.69/2.47E-03
L:(25/43)
1.85/3.66E-02
ASD 20
HLA-DQB1
Major
histocompatibility
complex, class II,
DQ beta 1
212998_x_at (I)
DE/4 51%
8 NS Gender/Dx
M-SZ
C:(11/64)
0.68/3.41E-02
F-MDD
C:(2/18)
1/1.23E-02
M-MDD
L:(13/43)
0.67/4.28E-02
Gender/Dx
M-BP
L:(34/91)
1.63/1.30E-02
Alcohol
Depression
Longevity stress
Suicide
SZ
Antipsychotics 20
HLA-DQB1
Major
histocompatibility
complex, class II,
DQ beta 1
211656_x_at (I)
DE/4 59%
8 NS Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
M-SZ
C:(11/64)
0.68/3.15E-02
M-SZ
C:(11/64)
0.74/5.90E-03
L:(7/39)
0.72/3.36E-02
M-MDD
L:(13/43)
0.69/2.68E-02
M-PSYCHOSIS
L:(10/56)
0.69/3.29E-02
Gender/Dx
M-MDD
C:(26/67)
0.62/4.85E-02
Alcohol
BP
Depression
Longevity
PTSD
Stress
Suicide
SZ
Antipsychotics 20
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
PNOC
Prepronociceptin
205901_at (I)
DE/4 62%
4 NS Gender/Dx
M-SZ
L:(7/39)
0.72/3.36E-02
Gender/Dx
M-BP
L:(9/80)
0.68/4.20E-02
Gender/Dx
M-BP
C:(53/134)
1.23/4.73E-02
L:(34/91)
1.26/2.67E-02
M-MDD
C:(42/72)
1.4/2.09E-02
Addictions
BP
MDD
SZ
Stress
20
TCF15
Transcription factor
15 (Basic helix-
loop-helix)
207306_at (D)
DE/6 94%
2 NS Gender/Dx
F-MDD
C:(2/18)
0.94/2.46E-02
M-MDD
L:(13/43)
0.68/3.21E-02
All
C:(239/501)
1.11/4.85E-02
Gender
Males
C:(226/454)
1.14/2.39E-02
Gender/Dx
M-BP
L:(34/91)
2.22/2.61E-03
Universal suicide
Male suicide
20
TOP3A
Topoisomerase
(DNA) III alpha
214300_s_at (D)
DE/4 51%
4 NS Gender/Dx
F-BP
C:(4/21)
0.84/1.97E-02
All
L:(145/309) 1.18/4.66E-02
Gender
Males
L:(138/282)
1.2/3.88E-02
Gender/Dx
M-SZ
L:(25/64)
1.75/4.72E-02
Omega-3 fatty
acids
20
(H05785)
LRRC75A
Leucine rich repeat
containing 75A
236913_at (D)
AP/6 97%
0 NS Gender/Dx
F-MDD
C:(2/18)
0.94/2.46E-02
All
C:(102/470)
0.56/2.27E-02
L:(58/287)
0.58/3.38E-02
Gender
Males
C:(95/426)
0.57/1.64E-02
L:(54/261)
0.59/2.71E-02
Gender/Dx
F-PTSD
C:(2/8)
1/2.28E-02
M-PSYCHOSIS
C:(33/198)
0.65/3.29E-03
M-SZA
C:(23/97)
0.68/5.21E-03
M-SZA
L:(13/55)
0.66/4.42E-02
M-MDD
L:(16/39)
0.76/3.64E-03
Alcohol
BP
Suicide
SZ
Clozapine 18
CLSPN
Claspin
242150_at (I)
AP/6 95%
0 NS Gender/Dx
M-PSYCHOSIS
C:(19/96)
0.65/2.48E-02
All
L:(58/287)
0.57/4.62E-02
Gender/Dx
F-MDD
L:(2/6)
1/3.20E-02
M-MDD
L:(16/39)
0.67/4.08E-02
Suicide 18
COL2A1
Collagen type II
alpha 1 chain
217404_s_at (D)
DE/4 54%
4 NS Gender
Males
C:(95/426)
0.56/3.53E-02
Gender/Dx
M-PSYCHOSIS
C:(33/198)
0.63/7.32E-03
M-SZA
C:(23/97)
0.66/1.08E-02
L:(13/55)
0.66/3.73E-02
Gender/Dx
M-PTSD
C:(26/31)
1.83/4.38E-03
L:(18/20)
2.3/1.08E-02
Aging 18
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
HLA-DQB1
Major
histocompatibility
complex, class II,
DQ beta 1
210747_at (D)
DE/2 44%
8 NS All
C:(239/501)
1.17/1.03E-02
Gender
Males
C:(226/454)
1.19/6.06E-03
Gender/Dx
M-MDD
C:(42/72)
1.35/3.68E-02
M-PSYCHOSIS
C:(95/201)
1.26/1.33E-02
M-SZA
C:(53/98)
1.33/2.06E-02
Addiction
Stress
Benzodiazepines 18
Hs.554262 210703_at (I)
AP/6
100%
0 NS All
C:(102/470)
0.56/2.38E-02
L:(58/287)
0.58/2.49E-02
Gender
Males
C:(95/426)
0.56/4.18E-02
L:(54/261)
0.59/1.65E-02
Gender/Dx
F-MDD
C:(4/11)
0.82/4.45E-02
M-BP
C:(18/120)
0.67/1.08E-02
M-MDD
L:(16/39)
0.67/4.08E-02
Gender/Dx
F-MDD
C:(4/12)
7/4.47E-02
M-MDD
L:(25/43)
2.13/7.30E-03
Suicide 18
PIK3CD
Phosphatidylinosi-
tol-4,5-
bisphosphate 3-
kinase catalytic
subunit delta
211230_s_at (D)
DE/6 83%
0 1.59E-02/4
Nominal
All
C:(239/501)
1.13/3.18E-02
Gender
Males
C:(226/454)
1.14/2.71E-02
Gender/Dx
M-BP
C:(53/134)
1.3/2.85E-02
L:(34/91)
1.57/2.01E-02
M-MDD
C:(42/72)
1.65/5.12E-03
Alcohol
Chronic stress
Longevity
Suicide
SZ
Clozapine
Lithium
Valproate
18
SVEP1
Sushi, von
willebrand factor
type A, EGF And
pentraxin domain
containing 1
236927_at (I)
DE/2 49%
4 2.17E-02/4
Nominal
Gender/Dx
F-PTSD
C:(5/12)
0.8/4.41E-02
M-PTSD
C:(13/38)
0.67/4.68E-02
Gender/Dx
F-MDD
C:(4/11)
0.82/4.41E-02
Addiction
SZ
Omega-3 fatty
acids
18
TNFRSF11B
TNF receptor
superfamily
member 11b
204932_at (D)
DE/2 37%
4 2.67E-02/4
Nominal
Gender/Dx
F-BP
C:(4/21)
0.81/3.00E-02
M-MDD
L:(13/43)
0.71/1.72E-02
Gender/Dx
M-MDD
C:(42/72)
1.42/4.25E-02
L:(25/43)
1.59/3.84E-02
Stress
PTSD
18
ZNF91
zinc ﬁnger protein
91
244259_s_at (I)
AP/6 95%
0 6.37E-01/2
Stepwise
Gender/Dx
F-MDD
C:(4/11)
0.93/1.17E-02
Gender
Females
C:(13/47)
2.12/1.03E-02
Gender/Dx
F-BP
C:(2/16)
4.21/4.55E-02
M-BP
C:(53/134)
1.35/1.26E-02
Alcohol
Circadian
abnormalities
PTSD
18
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
CDK6
Cyclin dependent
kinase 6
224851_at (I)
DE/4 56%
(I)
AP/2 42%
4 NS Gender/Dx
F-BP
C:(4/21)
0.78/4.44E-02
L:(3/11)
1/7.15E-03
All
C:(102/470)
0.57/1.03E-02
Gender
Males
C:(95/426)
0.59/5.57E-03
Gender/Dx
M-MDD
C:(26/67)
0.67/9.11E-03
Alcohol
ASD
Circadian
abnormalities
Longevity
MDD
SZ
17
EDN1
Endothelin 1
1564630_at (I)
AP/4 56%
4 8.69E-02/2
Stepwise
Gender
Females
C:(13/47)
1.9/1.48E-02
Gender/Dx
M-BP
C:(53/134)
1.27/2.37E-02
16
(AF090920)
PPFIBP2
PPFIA binding
protein 2
234739_at (I)
AP/6 94%
0 NS Gender
Female
C:(16/65)
0.68/1.42E-02
L:(10/36)
0.69/3.87E-02
Gender/Dx
F-PTSD
C:(5/12)
0.8/4.41E-02
Gender/Dx
M-PSYCHOSIS
C:(95/201)
1.19/3.77E-02
M-SZ
C:(42/103)
1.22/4.66E-02
16
DCAF12
DDB1 and CUL4
associated factor 12
224789_at (D)
DE/6 86%
2 NS Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
Gender/Dx
M-BP
C:(53/134)
1.61/4.42E-03
Cocaine
Suicide
Omega-3 fatty
acids
Clozapine
16
DNAJC18
DnaJ heat shock
protein family
(Hsp40) member
C18
227166_at (I)
DE/6 94%
0 NS Gender
Female
L:(10/36)
0.78/4.97E-03
Gender/Dx
F-SZA
L:(3/8)
0.93/2.63E-02
F-BP
L:(3/11)
0.88/3.31E-02
F-PSYCHOSIS
L:(3/8)
0.93/2.63E-02
F-PTSD
L:(3/6)
1/2.48E-02
Gender/Dx
F-MDD
C:(4/11)
0.93/1.17E-02
BP 16
HLA-DRB1
Major
histocompatibility
complex, class II,
DR Beta 1
208306_x_at (I)
AP/4 52%
4 NS Gender/Dx
F-MDD
C:(2/18)
0.91/3.39E-02
M-MDD
L:(13/43)
0.66/4.79E-02
M-SZ
L:(7/39)
0.71/4.27E-02
Gender/Dx
M-SZA
C:(23/97)
0.62/4.69E-02
Stress
PTSD
Antipsychotics 16
SEPT7P2
Septin 7
pseudogene 2
1569973_at (I)
DE/6
100%
(I)
AP/2 39%
0 NS Gender
Females
C:(16/65)
0.65/3.27E-02
Gender/Dx
F-PTSD
C:(5/12)
0.97/3.69E-03
M-SZ
C:(11/64)
0.77/2.83E-03
Gender/Dx
M-MDD
C:(42/72)
1.45/1.37E-02
L:(25/43)
2.25/5.24E-04a
M-PTSD
C:(26/31)
2.38/7.38E-04a
L:(18/20)
3.59/1.77E-03
Suicide 16
VEGFA
Vascular
endothelial growth
factor A
212171_x_at (I)
AP/4 65%
4 NS Gender/Dx
M-PSYCHOSIS
C:(19/96)
0.66/1.78E-02
M-SZA
C:(8/32)
0.7/4.48E-02
Gender/Dx
M-MDD
C:(42/72)
1.33/4.83E-02
BP
MDD
Stress
SZ
Lithium
Valproate
Olanzapine
16
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
WNK1
WNK lysine
deﬁcient protein
kinase 1
1555068_at (D)
DE/6 92%
2 NS Gender/Dx
M-MDD
L:(13/43)
0.77/2.75E-03
Gender/Dx
M-BP
C:(53/134)
1.41/3.18E-02
Alcohol
Depression
Suicide
Methamphetamine
Stress
Omega-3 Fatty
acids
SSRI
16
(AF087971)
PBRM1 Polybromo
1
1561067_at (I)
AP/6 90%
0 NS All
C:(102/470)
0.56/3.71E-02
Gender
Males
C:(95/426)
0.56/2.87E-02
Gender/Dx
M-BP
C:(18/120)
0.63/3.95E-02
M-PSYCHOSIS
C:(33/198)
0.63/8.63E-03
M-SZA
C:(23/97)
0.66/1.26E-02
BP
Hallucinations
Longevity
MDD
Methamphetamine
Mood psychosis
Stress
Suicide
14
(Hs.609761) SFPQ
Splicing factor
proline and
glutamine rich
244331_at (D)
DE/6 98%
0 NS Gender/Dx
M-SZ
C:(11/64)
0.68/3.28E-02
L:(7/39)
0.75/2.21E-02
Gender/Dx
M-MDD
C:(42/72)
1.68/7.35E-03
Alcohol
BP
MDD
Stress
Suicide
Omega-3 fatty
acids
Clozapine
Antidepressants
Antipsychotics
14
(Hs.659426) PHC3
Polyhomeotic
homolog 3
240599_x_at (D)
DE/6 92%
0 NS Gender/Dx
F-MDD
C:(2/18)
0.91/3.39E-02
Gender/Dx
M-MDD
C:(42/72)
1.48/1.83E-02
Suicide 14
CCDC85C
Coiled-coil domain
containing 85C
219018_s_at (D)
DE/6 94%
2 NS Gender
Female
L:(10/36)
0.7/3.31E-02
Gender/Dx
F-BP
C:(4/21)
0.79/3.66E-02
L:(3/11)
0.92/2.06E-02
F-PTSD
L:(3/6)
1/2.48E-02
Suicide 14
GSPT1
G1 To S phase
transition 1
215438_x_at (D)
DE/6 94%
0 NS Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
Gender/Dx
M-BP
C:(53/134)
1.58/4.92E-03
BP
Suicide
MDD
Valproate 14
HLA-DQB1
Major
histocompatibility
complex, class II,
DQ Beta 1
211654_x_at (I)
DE/2 40%
8 NS Gender/Dx
M-PSYCHOSIS
L:(10/56)
0.73/1.23E-02
M-SZ
L:(7/39)
0.81/5.78E-03
Alcohol
BP
Depression
Longevity
PTSD
Stress
Suicide
SZ
Antipsychotics 14
LOXL2
Lysyl oxidase like 2
228808_s_at (D)
DE/4 59%
4 NS Gender
Females
C:(16/65)
0.66/3.05E-02
Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
BP
Suicide
14
MBNL3
Muscleblind like
splicing regulator 3
219814_at (D)
DE/6 92%
0 NS Gender/Dx
M-MDD
L:(13/43)
0.71/1.51E-02
Gender/Dx
M-BP
C:(53/134)
1.43/8.16E-03
Psychosis
Hallucination
14
PTN
Pleiotrophin
211737_x_at (D)
DE/6 92%
0 NS All
C:(239/501)
1.16/1.17E-02
Gender
Males
C:(226/454)
1.2/4.66E-03
Gender/Dx
SZ
Stress
Suicide
Omega-3 fatty
acids
Risperidone
14
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Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
M-PSYCHOSIS
C:(95/201)
1.24/1.98E-02
M-SZA
C:(53/98)
1.35/1.28E-02
RALGAPA2
Ral GTPase
activating protein
catalytic alpha
subunit 2
231826_at (D)
DE/6 97%
0 NS Gender/Dx
F-MDD
C:(2/18)
0.94/2.46E-02
Gender/Dx
M-MDD
C:(42/72)
2.06/4.52E-04a
L:(25/43)
2.05/5.35E-03
BP 14
YBX3
Y-Box binding
protein 3
201160_s_at (D)
DE/6 94%
0 NS Gender/Dx
F-MDD
C:(2/18)
0.97/1.75E-02
Gender/Dx
M-BP
C:(53/134)
1.39/1.23E-02
BP
Suicide
SZ
Mianserin 14
ZNF441
Zinc ﬁnger protein
441
1553193_at (I)
AP/6 95%
(I)
DE/2 35%
0 NS Gender/Dx
M-SZA
L:(13/55)
0.67/3.13E-02
Gender/Dx
M-MDD
L:(25/43)
1.72/1.92E-02
14
CCND1
Cyclin D1
208712_at (D)
DE/4 57%
4 NS Gender/Dx
M-BP
C:(53/134)
1.33/4.53E-02
Addiction
MDD
Stress
Hallucinogens
12
CDK6
Cyclin-dependent
kinase 6
224847_at (I)
DE/4 63%
4 NS Gender/Dx
M-PTSD
L:(18/20)
2.09/1.75E-02
Alcohol
ASD
Circadian
abnormalities
Longevity
MDD
SZ
12
COMT
Catechol-O-
methyltransferase
213981_at (D)
DE/4 54%
4 NS Gender/Dx
M-MDD
L:(13/43)
0.71/1.41E-02
ADHD
Aggression
Alcohol
Anxiety
BP
Chronic stress
MDD
OCD
Panic disorder
Psychosis
PTSD
Suicide
SZ
Clozapine
Morphine
Mood stabilizers
12
HTR2A
5-
Hydroxytryptamine
receptor 2A
211616_s_at (D)
DE/4 52%
4 NS Gender/Dx
M-BP
L:(16/81)
0.65/2.89E-02
Addictions
Aging
Alcohol
Anxiety
BP
Depression
MDD
Mood disorders
NOS
OCD
Panic disorder
PTSD
Stress
Suicide
SZ
12
NF1
Neuroﬁbromin 1
212676_at (I)
DE/4 59%
4 NS Gender/Dx
F-BP
L:(3/11)
0.92/2.06E-02
Addiction
BP
PTSD
Fluoxetine
SSRI
12
SHMT1
Serine
hydroxymethyl-
transferase 1
217304_at (D)
DE/2 43%
6 NS Gender/Dx
F-PTSD
C:(2/8)
1/2.28E-02
M-SZA
L:(13/55)
0.7/1.54E-02
Suicide Clozapine 12
TSPO
Translocator
protein
202096_s_at (I)
DE/2 38%
6 NS Gender/Dx
M-SZ
C:(11/64)
0.72/1.06E-02
SZ 12
DENND1B
DENN domain
containing 1B
1557309_at (I)
DE/6
90%;
0 NS Gender/Dx
M-SZA
Omega-3 10
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did not work as well as individual biomarkers, particularly
when the later are tested by gender and diagnosis, consistent
with there being heterogeneity in the population and sup-
porting the need for personalization. The notable exception
was predicting longitudinally all future ED visits for pain,
where the panel of ﬁve validated biomarkers performed better
than individual biomarkers (Supplementary Information—
Complete Analyses). Importantly, predictions of future ED
visits for pain in the independent cohorts were consistently
stronger using biomarkers than clinical phenotypic markers
(pain VAS scale, pain items 21 and 22 from SF 36) (see
Supplementary Information—Complete Analyses), support-
ing the utility of biomarkers.
Fifth, we assessed if our biomarkers have evidence for
involvement in other psychiatric and related disorders
(Table S3). A majority of our biomarkers have some evi-
dence in other disorders, whereas a few seem to be speciﬁc
for pain, such as CCDC144B (Coiled-Coil Domain Con-
taining 144B), COL2A1 (Collagen Type II Alpha 1 Chain),
PPFIBP2 (PPFIA Binding Protein 2), DENND1B (DENN
Domain Containing 1B), ZNF441 (Zinc Finger Protein
441), TOP3A (Topoisomerase (DNA) III Alpha), and
ZNF429 (Zinc Finger Protein 429). A majority of our bio-
markers (50 out of 60 genes, i.e., 83.3%) have prior evi-
dence for involvement in suicide, suggesting an extensive
molecular co-morbidity between pain and suicide, to go
along with the clinical and phenomenological co-morbidity
(physical pain, psychic pain) [15]. We also analyzed the
biological pathways and networks our biomarkers are
involved in (Table S4 and Fig. 3). There is a network
centered on GNG7 (Fig. 3), that may be involved in con-
nectivity/signaling, comprising HTR2A, EDN1, PNOC
(involved in pain signaling) and CALCA (involved in
Reﬂex Sympathetic Dystrophy and Complex Regional Pain
Syndrome). It is reassuring that we see PNOC (Pre-
pronociceptin) increased in expression in high pain states,
i.e., as an algogene. Given its known roles in pain, it serves
as a de facto positive control. A second network is centered
on CCND1, may be involved in activity/trophicity, and
comprises HRAS, CDK6, PBRM1, CSDA, LOXL2, EDN1,
PIK3CD, and VEGFA. A third network is centered on HLA
DRB1, may be involved in reactivity/immune response, and
comprises GBP1, ZNF429, COL2A1, and HLA DQB1,
from our list of 65 top biomarkers.
Sixth, we identiﬁed which of our biomarkers are targets of
existing drugs and thus can be used for pharmacogenomics
population stratiﬁcation and measuring of response to treat-
ment (Table 2 and Table S5), as well as used the biomarker
gene expression signature to interrogate the Connectivity Map
database from Broad/MIT to identify drugs and natural
Table 2 (continued)
Gene symbol/gene
name
Probesets Step 1
Discovery
in blood
(direction
of change)
Method/
score/%
Up to 6 pts
Step 2
External
convergent
functional
genomics
(CFG)
Evidence for
involvement
in pain score
Up to 12 pts
Step 3
Validation
in blood
ANOVA
p-value/
score Up
to 6 pts
Step 4
Best signiﬁcant
prediction of
State-High Pain
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best Signiﬁcant
prediction of
Trait-Future ED
visits for Pain in
the ﬁrst year
(Cases/Total)
ROC AUC/
p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 4
Best signiﬁcant predictions
of Trait- Future ED visits for
Pain in all future years
(Cases/Total)
OR/OR p-value
8 pts All
6 pts Gender
4 pts Gender/Dx
Step 5
Other psychiatric
and related
disorders evidence
Step 6
Drugs That
Modulate the
Biomarker in
opposite
Direction to
Pain
CFE
Polyevidence
score for
involvement in
pain (based on
steps 1–4)
(I)
AP/2 40%
L:(3/17)
0.83/3.89E-02
MCRS1
Microspherule
protein 1
202556_s_at (I)
DE/6 90%
0 NS Gender/Dx
M-MDD
L:(13/43)
0.75/5.16E-03
MDD 10
OSBP2
Oxysterol binding
protein 2
1569617_at (D)
DE/6 94%
0 NS Gender/Dx
F-MDD
C:(2/18)
1/1.23E-02
Cocaine
Suicide
SZ
10
FAM134B
Family with
sequence similarity
134 member B
218510_x_at (I)
DE/4
51%;
(I)
AP/2 34%
4 NS Antisocial
personality
Suicide
Omega-3 fatty
acids
8
ZNF429
Zinc ﬁnger protein
429
1561270_at (D)
DE/2 37%
6 NS 8
(Hs.677263)
SMURF2
SMAD speciﬁc E3
ubiquitin protein
ligase 2
216444_at (D)
AP/6
100%
(D)
DE/4 71%
0 NS Aging
Suicide
Stress
6
DE differential expression, AP absent/present, NS non-stepwise in validation. For predictions, C-cross-sectional (using levels from one visit), L-
longitudinal (using levels and slopes from multiple visits). In All, by Gender, and personalized by Gender and Diagnosis (Gender/Dx). M males, F
Females, MDD depression, BP bipolar, SZ schizophrenia, SZA schizoaffective, PSYCHOSIS schizophrenia and schizoaffective combined, PTSD
post-traumatic stress disorder.
aSigniﬁcant after Bonferroni correction for the number of biomarkers tested (65). For Steps 2, 5 and 6, see Supplementary Information tables for
citations for the evidence.
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compounds that can be repurposed for treating pain (Table 3).
The top drugs identiﬁed as potential new pain therapeutic is
SC-560, an NSAID, haloperidol, and antipsychotic, and
amoxapine, an antidepressant. The top natural compounds
were pyridoxine (vitamin B6), cyanocobalamin (vitamin
B12), and apigenin (a plant ﬂavonoid).
Discussion
Biomarkers are emerging as important tools in disorders
where subjective self-report of an individual and/or clinical
impression of a healthcare professional are not always
reliable. Recent work by our group has identiﬁed blood
gene expression biomarkers that track suicidality using
powerful longitudinal within-subject designs, validated
them in suicide completers, and tested them in independent
cohorts demonstrating their ability to predict state (suicidal
ideation), and to predict trait (future hospitalizations for
suicidality) (Niculescu et al. [7], Levey et al. [2], Niculescu
et al. [8, 11]). Similar to suicidality, pain is a subjective
feeling, with objective roots. It may reﬂect past or current
injury events, their adverse consequences and compensatory
mechanisms. The rationale for identifying validated and
reproducible blood biomarkers is precisely because you
cannot directly biopsy brain and spinal centers of pain
perception. Blood biomarkers are easily accessible, and
constitute a surrogate (liquid biopsy).
We present work employing a powerful longitudinal
within-subject design, previously described by us for sui-
cidality [6–12], and used now to discover blood gene
expression changes between self-reported low pain and high
pain states. Gene expression is more powerful than genetics,
as it integrates a multitude of genetic variants and envir-
onmental effects. Longitudinal within-subject designs are
more powerful than case-control designs, and can provide
information with small Ns, as illustrated and discussed by
Snyder and colleagues [16–18], as well as Schork, Topol,
and colleagues [19, 20]. Some of these candidate gene
expression biomarkers are increased in expression in high
pain states (being putative risk genes), and others are
decreased in expression (being putative protective/resilience
genes). We cannot readily differentiate with our
Fig. 2 Best single biomarkers predictors. From the long list (n= 65).
Those on short list (n= 5) are bolded. Bar graph shows best predictive
biomarkers in each group. *Nominally signiﬁcant p < 0.05. **Bon-
ferroni signiﬁcant for the 65 biomarkers tested. Table underneath the
ﬁgures displays the actual number of biomarkers for each group whose
ROC AUC p-values (a, b) and Cox odds ratio p-values (c) are at least
nominally signiﬁcant. Some female diagnostic group are missing from
the graph as they did not have any signiﬁcant biomarkers. Cross-
sectional is based on levels at one visit. Longitudinal is based on levels
at multiple visits (integrates levels at most recent visit, maximum
levels, slope into most recent visit, and maximum slope). Dividing
lines represent the cutoffs for a test performing at chance levels
(white), and at the same level as the best biomarkers for all subjects in
cross-sectional (gray) and longitudinal (black) based predictions. All
biomarkers perform better than chance. Biomarkers performed better
when personalized by gender and diagnosis
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observational studies which of them are a reﬂection of
damage and which are compensatory mechanisms. How-
ever, given the fact that these biomarkers are discovered in
Step 1 by tracking present/state changes in the perception of
pain and not past/trait exposure, they may be more likely a
reﬂection of pathogenesis rather than adaptation.
Our systematic approach led to the identiﬁcation of
objective predictive biomarkers for pain, state and trait. We
present evidence for universal biomarkers for pain, as well
as show evidence that personalization by gender and diag-
nosis enhances precision, going from AUCs over 60% to
AUCs over 80%. A majority of the top biomarkers we have
identiﬁed overlap with biomarkers previously identiﬁed by
us in suicide, and almost all have evidence in other psy-
chiatric disorders (Table S3). Overlap and co-morbidity of
genetic ﬁndings are in general the rule, not the exception,
for neuropsychiatric disorders. Given the fact that pain
disorders and psychiatric disorders are highly co-morbid
clinically, that psychiatric medications are used to treat
pain, and that pain medications can have psychiatric effects,
the overlap is perhaps not surprising. It underlies the co-
morbidity and impact of pain on mental health and on
suicidality. Indeed, mood disorders were among the top
diseases identiﬁed by pathway analyses of our pain bio-
marker data (Table S4B).
The biomarkers with the best overall convergent infor-
mation evidence (CFE) across the multiple steps were
GNG7, CNTN1, LY9, CCDC144B, GBP1, and MFAP3
(Table 2). GNG7 (G Protein Subunit Gamma 7), with roles in
signal transduction, is decreased in expression in blood in
High Pain states in our work, i.e., it is a pain suppressor gene.
GNG7 is a strong predictor in the independent cohorts,
particularly for all future ED visits for pain. There is evidence
in other tissues in human studies for involvement in pain
(diabetic neuropathy [21], vertebral disc [22]). GNG7 is a
strong predictor in the independent cohorts, particularly for
Fig. 3 Biological roles. STRING interaction network for the top biomarkers for pain (65 probesets, 60 genes)
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all future ED visits for pain. GNG7 also has trans-diagnostic
evidence for involvement in other psychiatric disorders. It is
decreased in expression in mouse brain by alcohol, halluci-
nogens, and stress [23, 24, 25], and increased in expression
by omega-3 fatty acids. CNTN1 (Contactin 1), with roles in
neuronal cell adhesion, is decreased in expression in blood in
High Pain states in our work, i.e., it is a pain suppressor gene.
Reassuringly, there is a possible mechanistic basis for its
involvement in pain [26], and there is convergent evidence in
other tissues in human studies for involvement in pain:
CNTN1 has also been reported to be decreased in expression
in CSF in women with chronic widespread pain (CWP) [27].
Anti-contactin 1 autoantibodies, that block/decrease levels of
contactin 1, have been described in chronic inﬂammatory
demyelinating polyneuropathy [28]. Such reproducibility
across studies, tissues and populations provides strong rea-
sons to consider it as a bona ﬁde marker for pain, and it
serves as a reassuring de facto positive control for the design
and power of our study. CNTN1 has also trans-diagnostic
evidence for involvement in psychiatric disorders. It is
decreased in expression in schizophrenia brain [29] and
blood [30], and in blood in suicidality in females [8]. CNTN1
is increased in expression by clozapine in mouse brain [24].
LY9 (lymphocyte antigen 9), with immunomodulatory roles,
is increased in expression in blood in High Pain states in our
work, i.e., it is an algogene. LY9 is a good predictor in the
independent cohorts for state and trait, particularly for males
with MDD and PTSD. It also has epigenetic evidence for
involvement in exposure to stress [31], and is decreased in
expression by omega-3 fatty acids in mouse brain [32].
CCDC144B (Coiled-Coil Domain Containing 144B) is
decreased in expression in blood in High Pain states in our
work. There is evidence in other tissues in human [33] and
animal model [34] studies for involvement in pain.
CCDC144B is a good predictor in the independent
cohorts for state and trait, particularly for males with psy-
chosis (SZ, SZA). It does not have trans-diagnostic evidence
for involvement in other psychiatric disorders, seeming to be
relatively speciﬁc for pain. GBP1 (guanylate binding pro-
tein 1), with interferon induced signaling roles, is increased
in expression in blood in High Pain states in our work.
There is other evidence in human studies, gene expression
Table 3 Therapeutics
Rank CMAP name Score Description
1 SC-560 −1 SC-560 is an NSAID, member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors which
includes celecoxib (Celebrex™) and rofecoxib (Vioxx™). However, unlike these selective COX-2 inhibitors,
SC-560 is a selective inhibitor of COX-1.
2 Pyridoxine −0.997 Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body.
Pyridoxal 5-phosphate is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin,
norepinephrine), sphingolipids, aminolevulinic acid.
3 Methylergometrine −0.975 Methylergometrine is a synthetic analog of ergonovine, a psychedelic alkaloid found in ergot, and many
species of morning glory. It is chemically similar to LSD, ergine, ergometrine, and lysergic acid. Due to its
oxytocic properties, it has a medical use in obstetrics.
4 LY-294002 −0.923 LY-294002 is a potent, cell permeable inhibitor of phosphatidylinositol 3-kinase (PI3K) that acts on the ATP
binding site of the enzyme. The PI3K pathway has a role in inhibiting apoptosis in cancer. PI3K is also known
to regulate TLR-mediated inﬂammatory responses.
5 Haloperidol −0.917 Widely used typical antipsychotic medication
6 Cytisine −0.909 Like varenicline, cytisine is a partial agonist of nicotinic acetylcholine receptors (nAChRs), with an afﬁnity for
the α4β2 receptor subtype, and a half-life of 4.8 h.
7 Cyanocobalamin −0.902 Cyanocobalamin is a form of vitamin B12. Vitamin B12 is important for growth, cell reproduction, blood
formation, and protein and tissue synthesis.
8 Apigenin −0.899 Apigenin (4′,5,7-trihydroxyﬂavone), found in many plants such as chamomile, is a natural product belonging
to the ﬂavone class. Apigenin acts as a monoamine transporter activator, and is a weak ligand for central
benzodiazepine receptors in vitro and exerts anxiolytic and slight sedative effects in an animal model. It has
also effects on adenosine receptors and is an acute antagonist at the NMDA receptors (IC50= 10 μM). In
addition, like various other ﬂavonoids, apigenin has been found to possess nanomolar afﬁnity for the opioid
receptors, acting as a non-selective antagonist of all three opioid receptors.
9 Beta-escin −0.892 Escin, a natural mixture of triterpenoid saponins isolated from horse chestnut (Aesculus hippocastanum)
seeds, is used and studied as a vasoprotective anti-inﬂammatory, anti-edematous, and anti-nociceptive agent.
13 Amoxapine −0.875 Amoxapine is a tricyclic antidepressant of the dibenzoxazepine class. This drug is used to treat symptoms of
depression and neuropathic pain.
New drug discovery/repurposing. Connectivity Map [43, 44] (CMAP) analysis- drugs that have opposite gene expression proﬁle effects to our pain
biomarkers signatures (i.e., best is -1). Out of 65 probesets, 14 of the 29 increased, and 19 of the 36 decreased were present in HG-U133A array
used by Connectivity Map. A score of −1 indicates the perfect opposite match, i.e., the best potential therapeutic for pain. Drugs in Bold—drugs
known to treat pain, which thus serve as a de facto positive control for our approach. Drugs in Italic—natural compounds
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[33] and genetic [35], for involvement in pain. GBP1 is a
predictor in the independent cohorts for trait, particularly
in females. It is increased in expression in the brain in
MDD [36], schizophrenia [37, 38], and suicide [36], and
in blood in PTSD [39]. GBP1 is decreased in expression
by omega-3 in mouse brain [40]. Hs.666804/MFAP3
(microﬁbril associated protein 3), another of the top markers,
is a component of elastin-associated microﬁbrils. MFAP3
has the most robust empirical evidence from our discovery
and validation steps, and is a strong predictor in the inde-
pendent cohort, particularly for pain in females and males
with PTSD. Interestingly, it has no prior evidence for pain in
the literature curated to date for our Prioritization/CFG step,
which demonstrates that we are casting a wide-enough net
with our approach that can bring to the fore completely novel
ﬁndings. MFAP3 is decreased in expression in blood in High
Pain states in our work, i.e., it is a pain suppressor gene. It
also has previous evidence for involvement in alcoholism
[41], stress [42], and suicide [7, 9].
A phenotypic clustering analysis of the discovery
cohort revealed two broad putative subtypes of High
Pain states, a predominantly psychotic subtype, possibly
related to mis-connectivity and increased perception of
pain centrally, and a predominantly anxious subtype,
possibly related to reactivity and increased physical health
reasons for pain peripherally. Deeper analyses of the
clustering in future studies may also substantiate further
parsing of the subtypes, possibly into eight instead
of only two subtypes, and of underlying differentiating
biomarkers.
The biomarkers gene expression signatures also open the
door to drug repurposing approaches, including of nutra-
ceuticals. Nutraceuticals are particularly amenable to use in
preventive population level approaches.
In conclusion, our work opens the door for precision
medicine for pain, with objective diagnostics and targeted
novel therapeutics. Given the massive negative impact of
untreated pain on quality of life, the current lack of objec-
tive measures to determine appropriateness of treatment,
and the severe addiction gateway potential of existing
opioid-based pain medications, the importance of approa-
ches such as ours cannot be overstated.
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